Navigation Links
Studies show dramatic decline in rheumatoid vasculitis in US veterans
Date:8/26/2009

Researchers at the University of Wisconsin School of Medicine and Public Health examined records of rheumatoid arthritis (RA) patients from the national Veterans Health Administration (VHA) system to determine the prevalence of rheumatoid vasculitis (RV) in this population. The study found a downward trend in the number of RA patients who go on to develop RV, with a significant drop of 53% among inpatients and 31% among outpatients between 2000 and 2001. Full details of the study are published in the September issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.

Rheumatoid Vasculitis is a complication of severe RA, an autoimmune disease that causes painful inflammation of the joints. Approximately 2%-5% of RA patients develop RV, an extraarticular (occurring outside the joint) manifestation of rheumatoid arthritis, affecting small and medium-size arteries in the body. RV can involve many body organs including the skin, eyes, heart, lungs, nerves to the hands and feet, as well as blood vessels in the fingers and toes.

In this cross-sectional study, Christie Bartels, M.D., and colleagues from the University of Wisconsin School of Medicine analyzed data on patients admitted to VHA hospitals over a 22-year period (1985-2006) or seen in outpatient settings over a 10-year period (1997-2006). More than 37,000 patient records where a diagnosis of RA was noted qualified for the study and 92% of those being men with a mean age of 64.9 years. To determine a RV diagnosis, researchers included those patients who had one of the following: arteritis, mononeuritis multiplex (damage to multiple individual nerve fibers), peripheral neuropathy due to connective tissue disease, gangrene, or chronic ulcers.

A past study of data from California hospitals also showed hospitalizations for RV declined between 1980 and 2001. But analysis of only inpatient data raises questions of whether RV cases escaped detection due to changing outpatient management of the disease. "Our study is the first to examine a national U.S. population for RV prevalence among both inpatients and outpatients," stated Dr. Bartels. "We found the frequency of RV fell from 41 to 28 cases per 1,000 RA outpatients and from 32 to only 15 cases per 1000 RA inpatients."

Researchers believe the decline in RV reported in the current study may be attributed to: a decrease in the number of RV incidences, a disease cure in some patients, patients discontinuing VHA services or dying, or error. Treatment for rheumatoid arthritis improved throughout the 1990s and researchers speculate that the use of biologic agents and more aggressive combinations of anti-rheumatic drugs targeting severe RA may have diminished extraarticular disease, such as RV.

Additionally the authors noted that the VHA made system-wide efforts to decrease tobacco use among patients that may have impacted the rates of rheumatoid vasculitis prevalence. "Future studies should examine trends in smoking and pharmacotherapy in relation to RV, and ongoing monitoring is merited," concluded the authors.

This study included a greater number of men who were older than average RA patients and whose use of tobacco was likely higher than most RA cohorts. These demographics may limit the ability to apply the results to the general RA population. "Previous reports have described increased rates of extraarticular manifestations among men, smokers, and persons who were older at the time of RA onset, so perhaps the characteristics of our study sample facilitated detection of changes among the most at-risk population," Dr. Bartels surmised. "As RA treatment evolves, it will be important to continue following trends in rheumatoid vasculitis prevalence using samples with a sex ratio that more closely reflects the general population," she added.


'/>"/>

Contact: Dawn Peters
medicalnews@wiley.com
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. NIAID Awards New Grant to Expand Studies of Peregrines Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers
2. How diarrheal bacteria cause some colon cancers revealed in mouse studies
3. Studies do not support unhealthful relation between animal foods and breast cancer
4. Star Scientific Files Second Quarter Financial Results; Rock Creek Pharmaceuticals Reports Early Promising Results in Studies Assessing Safety and Viability of Active Components for a Non-Nicotine Nutraceutical (CigRx(TM))
5. Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading: Studies Actually Show it is Effective at Reducing Pain
6. Not-For-Profit Nursing Homes Fare Better in Studies
7. Put Defibrillators in High-Traffic Spots, Studies Urge
8. Rush University Medical Center studies program to help older adults transition from hospital to home
9. Stent Studies Tied to Rapid Changes in Use
10. Lilly to Unveil More Than 30 Studies at Premier Lung Cancer Meeting
11. SpeechEasy Seeks Proposals For Future Research Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... today announced that its MyDario product is expected to appear on The ... when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz ... The ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
Breaking Medicine Technology: